Introduction
The 2008 SSC guidelines use the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system, which classifies the quality of evidence as high (grade A), moderate (grade B), low (grade C), or very low (grade D), based on characteristics of study design and execution. Further, the GRADE system offers two grades of recommendation: strong (grade 1: desirable effects of the intervention clearly outweigh the undesirable effects) or weak (grade 2) recommendations.
Glucose control
In a single-centre prospective, randomised controlled trial (RCT) at the University Hospital in Leuven (Belgium), carried out between February 2000 and January 2001, Greet van den Berghe and colleagues showed that intensive insulin therapy to maintain euglycaemia (4.4-6.1 mmol/L) lowered in-hospital mortality from 10.9 to 7.2%, mostly by reducing deaths from multiple organ failure with a proven septic focus. 3 The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study, a multicentre, randomised, two-by-two factorial trial conducted in 18 intensive care units in Germany from April 2003 to May 2005, had to be stopped early for safety reasons. It showed no difference in mortality and mean score of organ failure at 28 days between the intensive insulin therapy group and the conventional therapy group. The use of intensive insulin therapy placed critically ill patients with sepsis at increased risk for serious adverse events related to hypoglycaemia. 4 In 2008, the SSC suggested:
"We recommend that, following initial stabilization, patients with severe sepsis and hyperglycaemia who are admitted to the ICU receive IV insulin therapy to reduce blood glucose levels (Grade 1B).
We suggest use of a validated protocol for insulin dose adjustments and targeting glucose levels to the <150 mg/dL (8.3 
mmol/L) range (Grade 2C).
We recommend that all patients receiving intravenous insulin receive a glucose calorie source and that blood glucose values be monitored every one to two hours until glucose values and insulin infusion rates are stable and then every four hours thereafter (Grade 1C).
We recommend that low glucose levels obtained with pointof-care testing of capillary blood be interpreted with caution as such measurements may overestimate arterial blood or plasma glucose values (Grade 1B)."

Recombinant human activated protein C (rhAPC)
Bernard and colleagues published a double-blind randomised controlled trial (PROWESS) that included 1,690 study patients from 164 centres in 11 countries. It was stopped after the second interim analysis, 5 which had shown a relative reduction in the risk of death of 19.4% and an absolute reduction of 6.1%. It also had demonstrated an increased risk of serious bleeding (3.5% vs 2.0%). After the PROWESS study, two other RCTs -the ADministration of DRotrecogin alfa (activated) in
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Early stage Severe Sepsis (ADDRESS) study and the REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspectiVE (RESOLVE) study -were both terminated early because of a low likelihood of meeting the prospectivelydefined objective to show a significant difference in their primary end points (28-day mortality rate). The ENHANCE study, an unblinded single-arm trial, showed a mortality benefit similar to PROWESS (25.3% at 28 days), but with a higher risk of bleeding (6.5%).
A Cochrane review of four studies involving 4,911 participants in 2007 concluded that rhAPC did not reduce the 28-day mortality in adult participants with severe sepsis. The effectiveness of rhAPC did not seem to be associated with the degree of severity of sepsis; rhAPC use was associated with a higher risk of bleeding. 6 The 2008 SSC Guidelines recommend:
"We suggest that adult patients with sepsis-induced organ dysfunction associated with a clinical assessment of high risk of death, most of whom will have APACHE II ≥25 or multiple organ failure, receive rhAPC if there are no contraindications (Grade 2B except for patients within 30 days of surgery where it is Grade 2C). Relative contraindications should also be considered in decision making.
We recommend that adult patients with severe sepsis and low risk of death, most of whom will have APACHE II <20 or one organ failure, do not receive rhAPC (Grade 1A)."
Corticosteroids
Djillali Annane and co-workers conducted a placebocontrolled, randomised, double-blind parallel-group trial in 19 intensive care units in France which concluded that seven-day treatment with low doses of hydrocortisone and fludrocortisone reduced the risk of death in patients with septic shock and relative adrenal insufficiency (diagnosed by response to a short adrenocorticotropin (ACTH) test)) from 63 to 53%, without increasing adverse events. 7 Reduced mortality was not seen in non-responders to the ACTH test. The Corticosteroid Therapy of Septic Shock (CORTICUS) study group conducted a multi-centre, randomised, double-blind placebo-controlled trial that concluded that hydrocortisone did not improve survival or reversal of shock in patients with septic shock. In the hydrocortisone group, there was an increased incidence of superinfections, hyperglycaemia and hypernatraemia. 8 The 2008 SSC guidelines recommend:
"We suggest intravenous hydrocortisone be given only to adult septic shock patients after blood pressure is identified to be poorly responsive to fluid resuscitation and vasopressor therapy (Grade 2C).
We suggest the ACTH stimulation test not be used to identify the subset of adults with septic shock who should receive hydrocortisone (Grade 2B)."
Methods
We sent out a questionnaire with 17 questions addressed to the lead clinicians of all 24 intensive care units in Scotland in May 2008. We repeated a second round to all non-responders in July 2008.
Results
We received replies from 21 out of the 24 general intensive care units in Scotland (87.5% response rate).
Glucose control
Nineteen units have a protocol for insulin therapy and have a consensus among consultants about this policy. Twenty units still use some form of glucose control. Nine units have changed their protocol/algorithm recently (see Table 1 ).
Recombinant human activated protein C
Results for rhAPC use are shown in Figure 1 . Ten units have their own protocol for the use of rhAPC. Two state that they use 'national guidelines' and nine units use no protocol. Fifteen units continue to use rhAPC on a regular basis, three 'occasionally,' one 'seems to have reduced' the use, one 'rarely' and one 'never' uses it. Nine units have a consensus between consultants about their policy. One statement says that there is 'consensus, but as a group we have some doubts.'
Corticosteroids
Eleven units have a protocol for use of steroids in severe sepsis.
Unit
Old target range New target range Seventeen units still use steroid substitution, one 'considers use,' two 'rarely use' or have 'mostly abandoned use' and one statement says that things are 'in flux.' Eleven units have a consensus view among clinicians. Eight units have changed their protocol recently and one unit has it currently under review. Results for corticosteroids use are shown in Figure 2 . Three units use intravenous hydrocortisone for every patient with septic shock when started on inotropic support (eg noradrenaline for persistent hypotension after adequate fluid resuscitation). Seventeen use it now only for patients with 'vasopressor-resistant' septic shock, as recommended in the 2008 SSC guidelines. One unit has stopped routine use of hydrocortisone in patients with severe sepsis.
Six units still use adrenocorticotrophin (ACTH) stimulation tests/short synacthen tests and 15 units do not use them at present. Of the first six units, two are currently reviewing their practice with a view to abandoning ACTH testing.
Discussion
The recommendations of the Surviving Sepsis Campaign guidelines of 2008 are classified as 'strong' (grade 1) for glucose control and 'weak' (grade 2) for the use of rhAPC and corticosteroids. The evidence is graded accordingly as 'moderate' (grade B) for glucose control and use of rhAPC (in adult patients with sepsis-induced organ failure and clinical assessment of a high risk of death) and 'low' for corticosteroids (grade C).
Our survey of clinical practice in intensive care units in Scotland shows that significant differences exist in the management of patients with severe sepsis in the different intensive care units in Scotland. Indeed this is the case between clinicians in the same unit. Two ICUs have no protocol for glucose control, nine have no specific written protocol for the use of rhAPC and 10 ICUs lack a protocol for steroid substitution ( Table 2) .
There seems to be agreement about the management of glucose control in most units, but around half of the units have no consensus between individual clinicians regarding the use of corticosteroids and rhAPC, and marked variety in the frequency of and indications for their use. There seems to be a majority trend to reserve steroid use for 'vasopressorresistant' septic shock and to give up ACTH stimulation testing. rhAPC or drotrecogin alfa (marketed as Xigris by Eli Lilly) has been controversial since its introduction. The FDA approved the drug in November 2001 despite the advisory committee's split vote (10 to 10) due to concerns about the validity of claimed efficacy and safety findings on the basis of a single trial. The 2004 SSC grading (B) and the involvement of Eli Lilly in marketing initiatives surrounding the implementation of the Surviving Sepsis Campaign have been heavily criticised. 9 The controversy about rhAPC is clearly not resolved, as documented by the fact that a significant proportion of ICUs (6/21; 28%) do not use it regularly. Overall it is worth noting that some individual units have given up glucose control, the use of rhAPC or corticosteroid substitution altogether.
New, much larger phase 3 clinical trials have been proposed in the search for more robust evidence. It has been suggested that the sample size should substantially exceed the total number of patients who have been studied so far. 10 Whether larger future trials will resolve the current uncertainties remains to be seen.
Unit
National No  protocol  guidelines  protocol   Glucose control  19  -2   rhAPC  10  2  9 Steroids 11 -10 
